Exact Sciences VP Dr. Isaac Kinde to Advise Owl Peak Technologies

Dr. Kinde plays a key role in evaluating technologies that enhance solutions across the cancer care continuum at Exact Sciences

Charlottesville, VA: May 13, 2025 - Owl Peak Technologies is thrilled to announce the addition of Dr. Isaac A. Kinde, M.D., Ph.D., as an advisor to our team. Dr. Kinde brings a wealth of expertise in cancer research and innovation, further strengthening our commitment to advancing healthcare technologies.

Dr. Kinde is currently Vice President of Technology Assessment at Exact Sciences. Previously, he served as Head of Research & Innovation and a Co-Founder of Thrive, where he pioneered tests for the earlier detection of cancer through simple blood draws. His groundbreaking work led to significant advancements in the early detection of various cancers and genetic diseases, utilizing improvements in massively parallel DNA sequencing technology.

During his graduate studies at Johns Hopkins University School of Medicine, Dr. Kinde's thesis research resulted in inventions that enable the earlier detection of cancers and other genetic diseases. His work, conducted under the mentorship of esteemed researchers Drs. Bert Vogelstein, Ken Kinzler, Nickolas Papadopoulos, and Luis Diaz, Jr., has been instrumental in the development of tests for ovarian and endometrial cancers from liquid-based Pap tests, recurrent bladder cancers from urine, and a variety of cancers from blood.

Dr. Kinde's contributions to the field are widely recognized, with descriptions of his inventions and their applications appearing in prominent scientific journals such as Proceedings of the National Academy of Sciences, Science, and Nature. He holds several issued patents and patent applications related to his research. In 2013, Dr. Kinde was honored as one of Forbes Magazine’s ‘30 under 30’ in Science and Healthcare.

Dr. Kinde holds a B.S. from the University of Maryland, Baltimore County, where he was a Meyerhoff Scholar, a Ph.D. in Cellular and Molecular Medicine, and an M.D. from Johns Hopkins University School of Medicine.

"We are delighted to welcome Dr. Isaac Kinde to Owl Peak Technologies," said Timothy Harvey, CEO of Owl Peak Technologies. "His innovative approach and extensive experience in cancer research will be invaluable as we continue to develop cutting-edge technologies to improve patient outcomes through advanced diagnostics."

Owl Peak Technologies is dedicated to revolutionizing healthcare through innovative cancer diagnostic solutions. With Dr. Kinde's guidance, we are confident in our ability to make significant strides in the early detection and treatment of cancer.

About Owl Peak Technologies
Owl Peak Technologies is a life sciences company that innovates hardware and software solutions that detect early-stage cancer more accurately and faster than current products on the market. For more information, visit www.owlpeaktechnologies.com.